

Lucia Moiola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/628578/publications.pdf>

Version: 2024-02-01

135
papers

5,083
citations

94269

37
h-index

114278

63
g-index

137
all docs

137
docs citations

137
times ranked

4762
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 374, 1503-1511.	6.3	551
2	Disease-modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	2.8	370
3	Neuropsychological features in childhood and juvenile multiple sclerosis. <i>Neurology</i> , 2014, 83, 1432-1438.	1.5	227
4	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.5	102
5	IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. <i>European Journal of Immunology</i> , 1998, 28, 2487-2497.	1.6	101
6	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005, 11, 420-424.	1.4	99
7	MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. <i>Neuroscience Letters</i> , 2012, 508, 4-8.	1.0	95
8	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1533-1538.	1.4	92
9	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1074-1083.	1.4	87
10	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
11	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012, 12, 124.	0.8	82
12	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012, 12, 165.	0.8	78
13	A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1076-1083.	1.4	77
14	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 329-334.	1.4	77
15	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 511-519.	1.4	76
16	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839.	1.5	74
17	Functional and Structural Connectivity of the Motor Network in Pediatric and Adult-Onset Relapsing-Remitting Multiple Sclerosis. <i>Radiology</i> , 2010, 254, 541-550.	3.6	72
18	Natalizumab in the pediatric MS population: results of the Italian registry. <i>BMC Neurology</i> , 2015, 15, 174.	0.8	72

#	ARTICLE	IF	CITATIONS
19	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009, 30, 193-199.	0.9	68
20	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 845-850.	0.9	66
21	Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients?. <i>Human Brain Mapping</i> , 2009, 30, 2844-2851.	1.9	64
22	Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1342-1347.	1.4	64
23	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1315-1326.	1.4	62
24	Treatment of early-onset multiple sclerosis with intramuscular interferon β -1a: long-term results. <i>Neurological Sciences</i> , 2007, 28, 127-132.	0.9	57
25	Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. <i>CNS Drugs</i> , 2017, 31, 33-50.	2.7	57
26	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , 2019, 92, e733-e741.	1.5	57
27	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1106-1112.	1.4	56
28	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , 2014, 82, 1314-1321.	1.5	56
29	Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects.. <i>Journal of Clinical Investigation</i> , 1994, 93, 1020-1028.	3.9	48
30	COVID-19 pandemic and mental distress in multiple sclerosis: implications for clinical management. <i>European Journal of Neurology</i> , 2020, 28, 3375-3383.	1.7	47
31	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016, 263, 1727-1735.	1.8	45
32	Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. <i>Journal of Neurology</i> , 2022, 269, 39-43.	1.8	44
33	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014, 75, 447-453.	2.8	43
34	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018, 265, 2851-2860.	1.8	43
35	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 467-470.	0.9	42
36	Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. <i>PLoS ONE</i> , 2016, 11, e0168376.	1.1	42

#	ARTICLE	IF	CITATIONS
37	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1506-1508.	1.4	41
38	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 347-359.	1.4	41
39	Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	41
40	Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. <i>Human Brain Mapping</i> , 2014, 35, 4180-4192.	1.9	40
41	Marchiafava-Bignami disease: longitudinal MR imaging and MR spectroscopy study. <i>American Journal of Neuroradiology</i> , 2003, 24, 249-53.	1.2	39
42	Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study. <i>Neurological Sciences</i> , 2016, 37, 235-242.	0.9	38
43	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 399-407.	1.4	38
44	Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1197-1206.	1.4	38
45	No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS. <i>Neurology</i> , 2017, 89, 2469-2475.	1.5	37
46	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	1.4	37
47	To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017, 82, 697-705.	2.8	35
48	Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 520-526.	0.9	34
49	Dysregulation of MS risk genes and pathways at distinct stages of disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e337.	3.1	34
50	T-Helper Epitopes on Human Nicotinic Acetylcholine Receptor in Myasthenia Gravis. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 198-218.	1.8	33
51	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1741-1749.	1.4	32
52	Pharmacogenetic study of long-term response to interferon- β treatment in multiple sclerosis. <i>Pharmacogenomics Journal</i> , 2017, 17, 84-91.	0.9	31
53	In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 10371.	1.6	31
54	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	31

#	ARTICLE	IF	CITATIONS
55	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014, 35, 307-316.	0.9	30
56	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , 2019, 85, 606-610.	2.8	30
57	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , 2017, 383, 166-168.	0.3	29
58	Gamma interferon activates a previously undescribed Ca ²⁺ influx in T lymphocytes from patients with multiple sclerosis.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 4825-4829.	3.3	28
59	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 628-640.	1.4	28
60	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2020, 17, 208-217.	2.1	28
61	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014, 14, 114.	0.8	27
62	Dynamic gray matter volume changes in pediatric multiple sclerosis. <i>Neurology</i> , 2019, 92, e1709-e1723.	1.5	27
63	Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1490-1499.	1.4	26
64	Myeloid cells as target of fingolimod action in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e157.	3.1	26
65	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 331-346.	1.4	26
66	Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor.. <i>Journal of Clinical Investigation</i> , 1992, 90, 1558-1567.	3.9	26
67	Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116603.	0.3	25
68	Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 702-707.	1.4	24
69	Brain macro- and microscopic damage in patients with paediatric MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1357-1362.	0.9	23
70	Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020, 33, 286-294.	1.8	23
71	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , 2015, 21, 956-959.	1.4	21
72	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013, 34, 1633-1637.	0.9	20

#	ARTICLE	IF	CITATIONS
73	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2015, 289, 62-67.	1.1	20
74	Practice of yoga may cause damage of both sciatic nerves: a case report. <i>Neurological Sciences</i> , 2013, 34, 393-396.	0.9	18
75	Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e129.	3.1	18
76	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , 2016, 2016, 1-9.	0.4	18
77	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 454-461.	1.0	18
78	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 167-174.	1.4	18
79	Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 403-405.	0.9	18
80	Inferring Multiple Sclerosis Stages from the Blood Transcriptome via Machine Learning. <i>Cell Reports Medicine</i> , 2020, 1, 100053.	3.3	18
81	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. <i>Neuroscience Letters</i> , 2012, 530, 155-160.	1.0	17
82	<i>In vivo</i> gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology. <i>Brain</i> , 2021, 144, 186-197.	3.7	17
83	Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes. <i>Brain</i> , 2021, 144, 848-862.	3.7	17
84	Validation of 1-year predictive score of long-term response to interferon- β in everyday clinical practice multiple sclerosis patients. <i>European Journal of Neurology</i> , 2015, 22, 973-980.	1.7	16
85	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 292-301.	1.4	16
86	Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1520-1532.	1.4	16
87	Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1752-1761.	0.9	15
88	Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment. <i>Molecular Psychiatry</i> , 2021, 26, 3634-3645.	4.1	14
89	COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. <i>Journal of Neurology</i> , 2020, 268, 2697-2699.	1.8	14
90	Interferon- β induces T lymphocyte proliferation in multiple sclerosis via a Ca ²⁺ -dependent mechanism. <i>Journal of Neuroimmunology</i> , 1995, 62, 169-176.	1.1	13

#	ARTICLE	IF	CITATIONS
91	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 799-805.	2.4	13
92	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , 2017, 89, 1265-1273.	1.5	13
93	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 75-77.	0.9	13
94	Early Predictors of 9â€­Year Disability in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 1011-1022.	2.8	13
95	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479.	1.4	13
96	Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. <i>Journal of Neurology</i> , 2018, 265, 896-905.	1.8	12
97	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 802-811.	1.4	11
98	Recurrence of disease activity after repeated Natalizumab withdrawals. <i>Neurological Sciences</i> , 2015, 36, 465-467.	0.9	11
99	Loss of Circulating CD8+ CD161high T Cells in Primary Progressive Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1922.	2.2	11
100	Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?. <i>Journal of the Neurological Sciences</i> , 2017, 378, 233-237.	0.3	10
101	Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. <i>Neurological Sciences</i> , 2018, 39, 1467-1470.	0.9	10
102	Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus. <i>Autoimmunity</i> , 2020, 53, 21-27.	1.2	10
103	Long-term follow-up (up to 11Â­years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. <i>Neurological Sciences</i> , 2022, 43, 6415-6423.	0.9	10
104	MGAT5 and disease severity in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 230, 143-147.	1.1	9
105	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e591.	3.1	9
106	Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. <i>Journal of Neurology</i> , 2019, 266, 3163-3166.	1.8	9
107	Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study. <i>Neurotherapeutics</i> , 2021, 18, 878-888.	2.1	9
108	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , 2017, 38, 361-364.	0.9	8

#	ARTICLE	IF	CITATIONS
109	Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports. <i>Neurological Sciences</i> , 2021, 42, 9-13.	0.9	8
110	Discontinuous distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 1990, 30, 129-134.	1.1	7
111	The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective. <i>Multiple Sclerosis International</i> , 2015, 2015, 1-7.	0.4	7
112	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. <i>Neurology</i> , 2022, 98, e1626-e1636.	1.5	7
113	Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1374-1383.	1.4	6
114	Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102145.	0.9	6
115	Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 21-34.	1.4	6
116	Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia. <i>Current Rheumatology Reports</i> , 2021, 23, 52.	2.1	6
117	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	4
118	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 447-453.	1.0	4
119	Neuromyelitis optica and myotonic dystrophy type 2: a rare association with diagnostic implications. <i>Journal of Neurology</i> , 2020, 267, 2744-2746.	1.8	4
120	Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?. <i>Journal of Neurology</i> , 2021, 268, 3975-3979.	1.8	4
121	Subacute visual loss and bilateral fixed mydriasis: an atypical case of giant cell arteritis. <i>Neurological Sciences</i> , 2014, 35, 1309-1310.	0.9	3
122	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. <i>Viruses</i> , 2016, 8, 128.	1.5	2
123	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. <i>European Journal of Neurology</i> , 2016, 23, e39-40.	1.7	2
124	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , 2016, 361, 184-186.	0.3	2
125	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 1005-1007.	1.8	2
126	Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117104.	0.3	2

#	ARTICLE	IF	CITATIONS
127	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , 2018, 384, 58-60.	0.3	2
128	HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis. <i>Neurological Sciences</i> , 2022, 43, 2095-2097.	0.9	2
129	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 57-59.	0.9	1
130	Successful treatment of HIV-associated tumefactive demyelinating lesions with corticosteroids and cyclophosphamide: a case report. <i>Journal of Neurology</i> , 2020, 267, 3773-3775.	1.8	1
131	Allogeneic Hematopoietic Stem Cell Transplantation For Severe Neuromyelitis Optica. <i>Blood</i> , 2013, 122, 5539-5539.	0.6	1
132	Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets. <i>Current Neuropharmacology</i> , 2022, 20, 1811-1815.	1.4	1
133	SAT0204...LUPUS LOW-DISEASE ACTIVITY STATE VS SLE RESPONDER INDEX IN A "REAL-LIFE" SETTING. , 2019, , .		0
134	09 Early macular atrophy at optical coherence tomography is predicted by visual evoked potentials and precedes peripapillary neurodegeneration after acute optic neuritis. <i>Clinical Neurophysiology</i> , 2017, 128, e182.	0.7	0
135	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-1a in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101952.	0.9	0